Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leona E Ling

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Current Pharmaceutical Biotechnology|May 31, 2011
Tgf-beta type I receptor (Alk5) kinase inhibitors in oncologyLeona E Ling, Wen-Cherng Lee
Blood Reviews|August 14, 2025
Targeting the neonatal Fc receptor (FcRn) in hematologic conditions with a focus on warm autoimmune hemolytic anemiaBruno Fattizzo, Leona E Ling, Wilma Barcellini
AJOG Global Reports|May 25, 2023
Live birth prevalence of hemolytic disease of the fetus and newborn in the United States from 1996 to 2010Devin Yu, Leona E Ling, Alexis A Krumme, et al.
Frontiers in Neuroscience|February 16, 2024
Pharmacokinetics and pharmacodynamics across infusion rates of intravenously administered nipocalimab: results of a phase 1, placebo-controlled studyJocelyn H Leu, An Vermeulen, Claudia Abbes, et al.
Cancer Immunology, Immunotherapy : CII|October 6, 2011
The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasisKendra Garrison, Tobias Hahn, Wen-Cherng Lee, et al.
Current Opinion in Drug Discovery & Development|September 2, 2004
Transforming the TGFbeta pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TbetaRI (ALK5)Juswinder Singh, Leona E Ling, J Scott Sawyer, et al.
Developmental Biology|September 23, 2003
A dual role for Sonic hedgehog in regulating adhesion and differentiation of neuroepithelial cellsArtem Jarov, Kevin P Williams, Leona E Ling, et al.
Clinical Drug Investigation|July 29, 2024
Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Neonatal Fc Receptor Blocker, in Healthy Japanese VolunteersNobuko Matsushima, Sayori Shibata, Jocelyn H Leu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunityEiji Suzuki, Veena Kapoor, H Kam Cheung, et al.
American Journal of Perinatology|March 6, 2025
Plain Language Summary of Publication: Design of the Phase 3 AZALEA Trial of Nipocalimab in Severe Hemolytic Disease of the Fetus and NewbornYosuke Komatsu, Victor Olusajo, Leona E Ling, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Current Pharmaceutical Biotechnology|May 31, 2011
Tgf-beta type I receptor (Alk5) kinase inhibitors in oncologyLeona E Ling, Wen-Cherng Lee
Blood Reviews|August 14, 2025
Targeting the neonatal Fc receptor (FcRn) in hematologic conditions with a focus on warm autoimmune hemolytic anemiaBruno Fattizzo, Leona E Ling, Wilma Barcellini
AJOG Global Reports|May 25, 2023
Live birth prevalence of hemolytic disease of the fetus and newborn in the United States from 1996 to 2010Devin Yu, Leona E Ling, Alexis A Krumme, et al.
Frontiers in Neuroscience|February 16, 2024
Pharmacokinetics and pharmacodynamics across infusion rates of intravenously administered nipocalimab: results of a phase 1, placebo-controlled studyJocelyn H Leu, An Vermeulen, Claudia Abbes, et al.
Cancer Immunology, Immunotherapy : CII|October 6, 2011
The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasisKendra Garrison, Tobias Hahn, Wen-Cherng Lee, et al.
Current Opinion in Drug Discovery & Development|September 2, 2004
Transforming the TGFbeta pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TbetaRI (ALK5)Juswinder Singh, Leona E Ling, J Scott Sawyer, et al.
Developmental Biology|September 23, 2003
A dual role for Sonic hedgehog in regulating adhesion and differentiation of neuroepithelial cellsArtem Jarov, Kevin P Williams, Leona E Ling, et al.
Clinical Drug Investigation|July 29, 2024
Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Neonatal Fc Receptor Blocker, in Healthy Japanese VolunteersNobuko Matsushima, Sayori Shibata, Jocelyn H Leu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunityEiji Suzuki, Veena Kapoor, H Kam Cheung, et al.
American Journal of Perinatology|March 6, 2025
Plain Language Summary of Publication: Design of the Phase 3 AZALEA Trial of Nipocalimab in Severe Hemolytic Disease of the Fetus and NewbornYosuke Komatsu, Victor Olusajo, Leona E Ling, et al.
Pageof 3